Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype.

Cardilo-Reis L, Gruber S, Schreier SM, Drechsler M, Papac-Milicevic N, Weber C, Wagner O, Stangl H, Soehnlein O, Binder CJ.

EMBO Mol Med. 2012 Oct;4(10):1072-86. doi: 10.1002/emmm.201201374.

2.

Attenuation of experimental atherosclerosis by interleukin-19.

Ellison S, Gabunia K, Kelemen SE, England RN, Scalia R, Richards JM, Orr AW, Traylor JG Jr, Rogers T, Cornwell W, Berglund LM, Goncalves I, Gomez MF, Autieri MV.

Arterioscler Thromb Vasc Biol. 2013 Oct;33(10):2316-24. doi: 10.1161/ATVBAHA.113.301521. Epub 2013 Aug 15. Erratum in: Arterioscler Thromb Vasc Biol. 2014 Jan;34(1):e1. Orr, Wayne [corrected to Orr, A Wayne].

3.

Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration.

Wang Y, Parlevliet ET, Geerling JJ, van der Tuin SJ, Zhang H, Bieghs V, Jawad AH, Shiri-Sverdlov R, Bot I, de Jager SC, Havekes LM, Romijn JA, Willems van Dijk K, Rensen PC.

Br J Pharmacol. 2014 Feb;171(3):723-34. doi: 10.1111/bph.12490.

4.

Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in mice.

Liu J, Huan C, Chakraborty M, Zhang H, Lu D, Kuo MS, Cao G, Jiang XC.

Circ Res. 2009 Jul 31;105(3):295-303. doi: 10.1161/CIRCRESAHA.109.194613. Epub 2009 Jul 9.

5.

Macrophage phenotypes in atherosclerosis.

Colin S, Chinetti-Gbaguidi G, Staels B.

Immunol Rev. 2014 Nov;262(1):153-66. doi: 10.1111/imr.12218. Review.

PMID:
25319333
6.

Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes.

Pinderski LJ, Fischbein MP, Subbanagounder G, Fishbein MC, Kubo N, Cheroutre H, Curtiss LK, Berliner JA, Boisvert WA.

Circ Res. 2002 May 31;90(10):1064-71.

7.

Overexpression of angiopoietin-like protein 4 protects against atherosclerosis development.

Georgiadi A, Wang Y, Stienstra R, Tjeerdema N, Janssen A, Stalenhoef A, van der Vliet JA, de Roos A, Tamsma JT, Smit JW, Tan NS, Müller M, Rensen PC, Kersten S.

Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1529-37. doi: 10.1161/ATVBAHA.113.301698. Epub 2013 May 2.

8.

The involvement of the monocytes/macrophages in chronic inflammation associated with atherosclerosis.

Fenyo IM, Gafencu AV.

Immunobiology. 2013 Nov;218(11):1376-84. doi: 10.1016/j.imbio.2013.06.005. Epub 2013 Jun 19.

PMID:
23886694
9.

Macrophage ABCA2 deletion modulates intracellular cholesterol deposition, affects macrophage apoptosis, and decreases early atherosclerosis in LDL receptor knockout mice.

Calpe-Berdiel L, Zhao Y, de Graauw M, Ye D, van Santbrink PJ, Mommaas AM, Foks A, Bot M, Meurs I, Kuiper J, Mack JT, Van Eck M, Tew KD, van Berkel TJ.

Atherosclerosis. 2012 Aug;223(2):332-41. doi: 10.1016/j.atherosclerosis.2012.05.039. Epub 2012 Jun 12.

10.

Systemic deficiency of the MAP kinase-activated protein kinase 2 reduces atherosclerosis in hypercholesterolemic mice.

Jagavelu K, Tietge UJ, Gaestel M, Drexler H, Schieffer B, Bavendiek U.

Circ Res. 2007 Nov 26;101(11):1104-12. Epub 2007 Sep 20.

11.

Minimally oxidized LDL offsets the apoptotic effects of extensively oxidized LDL and free cholesterol in macrophages.

Boullier A, Li Y, Quehenberger O, Palinski W, Tabas I, Witztum JL, Miller YI.

Arterioscler Thromb Vasc Biol. 2006 May;26(5):1169-76. Epub 2006 Feb 16.

12.

Proatherogenic macrophage activities are targeted by the flavonoid quercetin.

Lara-Guzman OJ, Tabares-Guevara JH, Leon-Varela YM, Álvarez RM, Roldan M, Sierra JA, Londoño-Londoño JA, Ramirez-Pineda JR.

J Pharmacol Exp Ther. 2012 Nov;343(2):296-306. doi: 10.1124/jpet.112.196147. Epub 2012 Aug 6.

13.

Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Krüppel-like factor 2.

van Tits LJ, Stienstra R, van Lent PL, Netea MG, Joosten LA, Stalenhoef AF.

Atherosclerosis. 2011 Feb;214(2):345-9. doi: 10.1016/j.atherosclerosis.2010.11.018. Epub 2010 Nov 27.

14.

IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis.

Erbel C, Akhavanpoor M, Okuyucu D, Wangler S, Dietz A, Zhao L, Stellos K, Little KM, Lasitschka F, Doesch A, Hakimi M, Dengler TJ, Giese T, Blessing E, Katus HA, Gleissner CA.

J Immunol. 2014 Nov 1;193(9):4344-55. doi: 10.4049/jimmunol.1400181. Epub 2014 Sep 26.

15.
16.

Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor.

Zhao L, Ding T, Cyrus T, Cheng Y, Tian H, Ma M, Falotico R, Praticò D.

Br J Pharmacol. 2009 Mar;156(5):774-85. doi: 10.1111/j.1476-5381.2008.00080.x. Epub 2009 Feb 13.

17.

Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice.

Verreth W, De Keyzer D, Davey PC, Geeraert B, Mertens A, Herregods MC, Smith G, Desjardins F, Balligand JL, Holvoet P.

Br J Pharmacol. 2007 Jun;151(3):347-55. Epub 2007 Mar 26.

18.

Macrophages transmit potent proangiogenic effects of oxLDL in vitro and in vivo involving HIF-1α activation: a novel aspect of angiogenesis in atherosclerosis.

Hutter R, Speidl WS, Valdiviezo C, Sauter B, Corti R, Fuster V, Badimon JJ.

J Cardiovasc Transl Res. 2013 Aug;6(4):558-69. doi: 10.1007/s12265-013-9469-9. Epub 2013 May 10.

19.

The nitroxide radical TEMPOL prevents obesity, hyperlipidaemia, elevation of inflammatory cytokines, and modulates atherosclerotic plaque composition in apoE-/- mice.

Kim CH, Mitchell JB, Bursill CA, Sowers AL, Thetford A, Cook JA, van Reyk DM, Davies MJ.

Atherosclerosis. 2015 May;240(1):234-41. doi: 10.1016/j.atherosclerosis.2015.03.012. Epub 2015 Mar 16.

PMID:
25818249
20.

MicroRNA profiling reveals opposing expression patterns for miR-511 in alternatively and classically activated macrophages.

Karo-Atar D, Itan M, Pasmanik-Chor M, Munitz A.

J Asthma. 2015;52(6):545-53. doi: 10.3109/02770903.2014.988222.

PMID:
25405361

Supplemental Content

Support Center